Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Stage IB Lung Adenocarcinoma

Known as: Stage IB Adenocarcinoma of Lung, Stage IB Adenocarcinoma of the Lung, Stage IB Lung Adenocarcinoma AJCC v7 
Stage IB includes: T2a, N0, M0. T2a: Lung cancer with a tumor size more than 3 cm but 5 cm or less in greatest dimension. N0: No regional lymph… Expand
National Institutes of Health

Related topics

Related topics

28 relations
ALK geneChestChromosome 13q deletionCoughing
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Survival prediction and adjuvant chemotherapy based on tumor marker for stage IB lung adenocarcinoma.
BACKGROUND We aimed to find out the prognosis of stage IB invasive lung adenocarcinoma according to perioperative tumor markers… Expand
2018
2018
Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma
Objective: To evaluate the prognostic significance and beneficiaries of adjuvant chemotherapy (ACT) in various histological… Expand
  • figure 1
  • table 1
  • table 1
  • table 2
  • table 3
Review
2018
Review
2018
Squamous Cell Carcinoma Transformation from EGFR‐mutated Lung Adenocarcinoma: A Case Report and Literature Review
Epidermal growth factor receptor (EGFR)-mutated nonesmall-cell lung cancer responds dramatically to initial EGFR tyrosine kinase… Expand
  • figure 1
  • figure 2
2018
2018
Micropapillary or solid pattern predicts recurrence free survival benefit from adjuvant chemotherapy in patients with stage IB lung adenocarcinoma.
Background Our study aimed to evaluate the prognostic significance and adjuvant chemotherapy (ACT) benefits of a micropapillary… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
2017
2017
Effect of Adjuvant Chemotherapy after Complete Resection for Pathologic Stage IB Lung Adenocarcinoma in High-Risk Patients as Defined by a New Recurrence Risk Scoring Model
Purpose We conducted a retrospective analysis to determine if adjuvant chemotherapy prolongs overall survival in patients with… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
2016
2016
Adjuvant Chemotherapy Improves the Probability of Freedom From Recurrence in Patients With Resected Stage IB Lung Adenocarcinoma.
BACKGROUND The benefit of adjuvant chemotherapy remains controversial for patients with stage IB non-small-cell lung cancer… Expand
2015
2015
Solid component and tumor size correlate with prognosis of stage IB lung adenocarcinoma.
BACKGROUND Prognostic factors for stage IB lung cancer remain controversial. The International Association for the Study of Lung… Expand
2015
2015
Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification in stage IB lung adenocarcinoma.
  • C.–h. Xu, W. Wang, +6 authors Y. Wang
  • European journal of surgical oncology : the…
  • 2015
    • Corpus ID: 7561980
BACKGROUND Patients with pathological stage IB lung adenocarcinoma have a variable prognosis, even if received the same treatment… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
2014
2014
Correlation of survival and EGFR mutation with predominant histologic subtype according to the new lung adenocarcinoma classification in stage IB patients
BackgroundA new lung adenocarcinoma classification proposed by the International Association for the Study of Lung Cancer… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Review
2008
Review
2008
Identification of a low risk subgroup of stage IB lung adenocarcinoma patients.
OBJECTIVES Several trials have recently reported the efficacy of adjuvant chemotherapy for resected stage IB non-small cell lung… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE